2019
Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma
Deshmukh U, Black J, Perez-Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Rutherford TJ, Santin AD, Azodi M, Silasi DA, Ratner E, Litkouhi B, Schwartz PE. Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma. Reproductive Sciences 2019, 26: 600-608. PMID: 29843577, DOI: 10.1177/1933719118778801.Peer-Reviewed Original ResearchConceptsLow-grade endometrial stromal sarcomaRecurrence-free survivalStage I patientsEndometrial stromal sarcomaAromatase inhibitorsI patientsStage IIStromal sarcomaAdvanced low-grade endometrial stromal sarcomaMean recurrence-free survivalLonger recurrence-free survivalAdjuvant hormonal therapyMedian followProgestin groupUnderwent hysterectomyHormonal therapyDisease recurrenceSide effectsPatientsStage IProgestinsMonthsSarcomaDiseaseTreatment
2005
3 Role of Immunohistochemical Expression of HER2/neu in High-Grade Ovarian Serous Papillary Cancer
Santin A. 3 Role of Immunohistochemical Expression of HER2/neu in High-Grade Ovarian Serous Papillary Cancer. Handbook Of Immunohistochemistry And In Situ Hybridization Of Human Carcinomas 2005, 4: 333-338. DOI: 10.1016/s1874-5784(05)80089-3.Peer-Reviewed Original ResearchHER2/neuEpidermal growth factor receptorHER2/neu protein overexpressionLymphocyte-activated killer cellsTumor necrosis factor alphaHER2/neu overexpressionPapillary cancer tissuesVascular endothelial growth factorNecrosis factor alphaShorter patient survivalHER2/neu functionNeu protein overexpressionEndothelial growth factorHER2/neu gene productGrowth factor receptorHormonal therapyKiller cellsGynecologic tumorsPatient survivalPapillary cancerNeu overexpressionOvarian carcinomaHistologic evaluationImmunohistochemical expressionDifferential diagnosis